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Abstract Cyclic vomiting syndrome (CVS) was ini-
tially described in children but can occur in all age
groups. Cyclic vomiting syndrome is increasingly
recognized in adults. However, the lack of awareness
of CVS in adults has led to small numbers of diag-
nosed patients and a paucity of published data on the
causes, diagnosis and management of CVS in adults.
This article is a state-of-knowledge overview on CVS
in adults and is intended to provide a framework for
management and further investigations into CVS in
adults.
Keywords cyclic vomiting syndrome, dyspepsia,
gastroparesis.
INTRODUCTION
Cyclic vomiting syndrome (CVS) is a disorder charac-
terized by recurrent episodes of severe nausea and
vomiting interspersed with symptom-free periods. This
syndrome was first described in the English literature
in 1882 by Samuel Gee1 who reported a series of nine
children ranging from 4 to 8 years in age. While CVS
has been studied in paediatric populations,2,3 its
occurrence in adults has been underappreciated. It is
now apparent that this disabling illness affects all ages,
including young and middle aged adults. Knowledge
about CVS in adults is more limited than in children
and generally is based on retrospective case series.
Although the disorder in children and adults probably
represents a continuum, some evidence suggests there
may be differences in paediatric and adult CVS in
terms of symptom profiles, pathogenesis and associ-
ated comorbidities (Table 1). Indeed, in contrast to
most childhood cases, a subset of adult patients
develops a CVS-like disorder which is secondary to
other chronic systemic diseases or, in some cases,
appears to be associated with substance abuse.
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This manuscript is intended for two purposes. The
first is to provide an overview of CVS in adults and a
framework of the disorder for adult and paediatric
gastroenterologists, gastrointestinal (GI) motility spe-
cialists, internists, neurologists, psychologists and
basic scientists. The second is to introduce the disor-
der, the diagnostic criteria, management and current
theories of pathogenesis to clinicians and scientists
who diagnose, manage and investigate these patients.
This article, in part, was derived from the proceedings
of two expert panel meetings on adult CVS sponsored
by the Cyclic Vomiting Syndrome Association (CVSA)
and the American Neurogastroenterology and Motility
Society: (i) CVS Across the Ages; June 3–4, 2006 at the
Medical College of Wisconsin and CVS in Adults; (ii)
September 17, 2006 in Boston, MA at the American
Neurogastroenterology and Motility Society Meeting.
CLINICAL PRESENTATION AND
SPECTRUM
Clinical symptoms of CVS in children
Large databases of paediatric patients with CVS main-
tained by Chong in England (108 patients) and Li in the
USA (463 patients) provide remarkably similar clinical
descriptions of paediatric patients with CVS.4–6 Dis-
crete vomiting episodes lasting from 2 h to 10 days
occur in 93–100% of children and are accompanied by
symptoms of nausea, retching and abdominal pain in
four-fifths of patients. Common triggering factors
include stress, emotional excitement and infections.
The episodes are severe with at least four emeses per
hour when at its worse in 71–77% of patients.
Abdominal pain accompanies these episodes in
67–80% of patients. Affected children generally have
four to 12 episodes per year. Between episodes, the
majority of children (63–94%) are well; however in the
UK study, more than one-third of patients are not
symptom free in between episodes, suggesting a heter-
ogeneous aetiology or a coalescing syndrome. The
average age at initial diagnosis is 5 years of age,
however, this diagnosis is typically delayed for several
years.6 A family history of migraine is present in
67–82% of cases.5 This paediatric presentation is well
described in previous reviews3,6 and listed in Table 1.
Paediatric CVS has been reported to have a prevalence
of 0.04–1.9% of children7,8 with an incidence of new
cases to be approximately 3 per 100 000 children per
year.9 The natural history of CVS in children is
variable: some patients will ultimately cease to have
emetic episodes, some switch from having vomiting
episodes to having migraine headaches, whereas some
continue to have vomiting episodes.7,8
Clinical symptoms and epidemiology of CVS
in adults
As in children, adults with CVS experience multiple
episodes of vomiting with frequent visits to Emergency
Departments (EDs) for relief of nausea, vomiting and
resultant dehydration. Table 1 compares the charac-
teristics of adults and children with CVS. Episodes are
accompanied by severe abdominal pain in approxi-
mately 58–71% of adult patients.10,11 Triggers of acute
emetic episodes are similar for adults and children
Table 1 Comparison of adults and chil-
dren with cyclic vomiting syndromeChildren Adults
Age at diagnosis 4.6–5.3 years 34.8 years
Delay in diagnosis 2.6–3.1 years 7.9 years
Duration of episodes 2.0 days 3.8 days




Abdominal pain Common (72–80%) Common (58–71%)
UGI complications Common (22–32%) Common (38%)
Interepisodic nausea or dyspepsia Rare Common
Associated psychiatric manifestations Common Common
Migraine headache or family
history of migraine headache
Common (39–82%) Common (24–70%)
Mitochondrial DNA disorders Reported Not reported
Disorders of fatty acid metabolism Rare Not reported
Cannabis abuse Not reported Reported
Data from Fleisher and Matar3, Fleisher et al.10, Prakash et al.11, Namin et al.14 and
Li and Balint6.
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with CVS and include infections (e.g. chronic sinusitis
and other upper respiratory infections), psychological
stress, motion sickness, lack of sleep, physical exhaus-
tion and certain food products (e.g. chocolate, cheese,
monosodium glutamate).12,13 In some women, epi-
sodes also can be triggered by menses – a phenomenon
termed catamenial CVS. Adult patients with CVS
often remain undiagnosed for some time due to a lack
of recognition of this clinical entity with reports
suggesting a delay in diagnosis for up to 8–21 years
following disease onset.10,11 In emergency rooms,
patients may be presumed to have viral gastroenteritis
or food poisoning. Some patients are thought to have
gastroparesis, a disorder typified by chronic nausea and
vomiting. In one study, 5% of patients referred to a
major medical centre for evaluation of gastroparesis
had CVS.14 Patients who are undiagnosed are some-
times subjected to surgery that usually does not alter
the course of their illness. Thirty-nine per cent of a
series of 41 adults with undiagnosed CVS underwent
one or more surgical procedures (most commonly
cholecystectomy).10 Other patients are speculated to
have psychiatric disorders such as conversion disorder,
eating disorders, or personality disorders to explain
their unusual symptom presentations. Some patients
may be suspected or accused of being drug seeking
because narcotics are often given for the abdominal
pain in the ED. Finally, the lack of a diagnosis and
appropriate treatment programmes result in many
patients with CVS experiencing severely impaired
quality of life due to the repeated episodes of vomiting,
emergency intervention and hospitalization. Both
patients and their families often suffer economically
and socially when the symptoms interfere with day-
to-day life including education, job performance and
marriage. Disability is commonly associated with
adult onset CVS.
Cyclic vomiting episodes are stereotypic for each
individual patient and characterized by four phases in
many adults:10,11
1 The interepisodic well phase occurs between vom-
iting episodes when the patient is relatively symp-
tom-free. This phase typically last weeks to months.
2 The pre-emetic or prodromal phase occurs when the
patient begins to sense the approach of an episode
but may still be able to keep down oral medications.
The usual prodromal symptom is nausea of varying
intensity, but may include abdominal pain, lethargy,
anorexia and pallor. This phase lasts minutes to
hours.
3 The emetic phase is characterized by intense,
persistent nausea, repeated vomiting and other
symptoms (pallor, abdominal pain, prostration and
listlessness). This phase lasts from hours to days.
4 The recovery phase begins with termination of
vomiting and ends when hunger, tolerance of oral
intake and vigour returns.
Criteria for the diagnosis of CVS in adults were
published by the Rome III working teams on functional
GI disorders in 2006 (Table 2).15 There have been
several case series reported in the literature describing
the demographic, clinical and psychological character-
istics of adult patients (ages 18–62 years) with CVS
(Table 3).10,11,14,16,17 In a series of 41 adult patients
with CVS, Fleisher et al.10 found the age of onset of
symptoms ranged from 2 to 49 years and the delay in
diagnosis from onset of symptoms averaged 21 years.
Table 2 Rome III diagnostic criteria for cyclic vomiting
syndrome in adults
The following three criteria must be fulfilled for the last
3 months with symptom onset at least 6 months before
diagnosis
1 Stereotypical episodes of vomiting regarding onset
[acute and duration (less than 1 week]
2 Three or more discrete episodes in the prior year
3 Absence of nausea and vomiting between episodes
Supportive criteria for the diagnosis of cyclic vomiting
syndrome includes personal or family history of migraine
headaches. Source: Ref. 15.




of publication No. adults
Age at onset of
Sx average (range) Attack duration
Frequency of
attacks
Abell et al.17 1988 (manuscript) 8 (5M, 3F) NR 3.5 days 3.2 months
Prakash et al.11 2001 (manuscript) 21 (9M, 12F) 34.8 ± 3.8 years 3.8 ± 0.4 days 3.1 ± 0.4 months
Fajardo et al.16 2005 (abstract) 50 (28M, 22F) NR NR NR
Fleisher et al.10 2006 (manuscript) 41 (24M, 17F) 21 (2–49) years 3–4 days NR
Namin et al.14 2007 (manuscript) 31 (18M, 13F) 30 (14–53) years 5 (1–14) days NR
NR, not reported.
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In parallel to findings in children, 70% of adults in his
case series reported migraine headaches between or
during episodes and psychological disturbances such as
panic attacks were common (Table 1). However, in
contrast to classic paediatric patients with CVS, 50–
63% of adult patients with CVS experienced interep-
isodic nausea. In another case series, the most consis-
tent findings were the stereotypical nature of the
attacks of nausea, vomiting and abdominal pain
between symptom-free periods.14 These characteristics
are similar to CVS in children, although the episode
duration appears to be more prolonged (3–6 days) in
adults.3,11
Recent published observations in adults and unpub-
lished ones in children indicate that some patients can
progress from a pattern of discrete emetic episodes to a
pattern of nearly continuous nausea and vomiting.10
This form of disease, termed coalescent CVS, appears
to be more common in adults than in children. These
patients suffer subacute symptoms of nearly continu-
ous nausea and frequent emesis lasting weeks to
months that can result in profound weight loss requir-
ing special nutritional support. Coalescent patients
are usually unable to work or attend school. One-third
of a series of 41 adults were disabled and required
financial support.10 As coalescence is most often
observed in patients with untreated CVS, it may
represent an evolving form of CVS. When appropriate
treatment interventions are pursued, or treatment is
optimized, many patients improve but the cause of this
disorder and whether the pathophysiology of this
disorder differs from the more typical CVS with well
episodes between ill episodes, is unclear.
A cyclic pattern of symptoms may occur in some
individuals who do not meet strict criteria for CVS, but
nevertheless may have discrete exacerbation of symp-
toms. A subset of individuals with diabetes mellitus
experiences episodic vomiting with symptom free
intervals as in CVS.18 In addition, another subgroup
of diabetic patients with documented gastroparesis also
report cyclic episodes of vomiting, and meet the
criteria for both conditions. Abdominal pain with or
without diarrhoea can also precede the onset of vom-
iting, suggesting a CVS-like disorder may be a mani-
festation of severe irritable bowel syndrome. Another
variant of CVS presents with recurrent morning nausea
with limited vomiting which resolve later in the day,
permitting normal functioning and food intake. These
patients may never achieve a full blown attack requir-
ing admission.
A rare syndrome of recurrent vomiting associated
with hypertension and profound listlessness during
episodes has been reported in children with CVS-like
conditions by Sato et al.19–21 Similarly, Pasricha
et al.22 have described an adult with cyclic vomiting




Conditions observed to co-exist in adults with CVS
include migraine headaches, psychiatric disease,
chronic marijuana use, gastro-oesophageal reflux dis-
ease, irritable bowel syndrome, gallbladder disease and
insulin-dependent diabetes mellitus.
Migraine headache Migraine headaches and/or a fam-
ily history of migraines are present in 39–82% of
children with CVS and 24–70% of adults with CVS.2,11
Migraine headaches occur commonly in adult patients
with CVS whereas many children have not yet devel-
oped them. Migraines may develop in children with
CVS as they reach adolescence, with associated loss of
the emetic disorder. Some adults may give a remote
history of migraine, but do not currently experience
headaches. In addition, a family history of migraine is
also prevalent among patients with CVS who them-
selves may not have migraine.2,23 This association
between migraine and CVS was first suggested by
Whitney in 1898 and has since been confirmed in
multiple studies that have further observed homology
of symptoms during CVS and migraine episodes (e.g.
pallor, lethargy, nausea, abdominal pain), stereotypy of
attacks and the high prevalence of familial migraines
in both disorders (up to 72%).2 The family history of
migraine in patients with CVS is particularly promi-
nent in the maternal lineage. As will be discussed, the
maternal inheritance pattern of migraines and CVS
suggest that CVS may be in part inherited through
mitochondrial DNA (mtDNA).24
Migraine headache, abdominal migraine and CVS are
functional disorders that seem to be manifestations of
a common diathesis. Each is characterized by stereo-
typic, self-limited episodes. Patients often experience
symptoms of the other two disorders. Their nosological
distinction is based on their predominant symptoms:
headache in migraine, intense abdominal pain in
abdominal migraine, and nausea and vomiting in
CVS.22 The prevalences of CVS, abdominal migraine
and migraine headaches peak at ages 5, 10 and 11 years
respectively.7 Individual patients may progress from
one disorder to the others over time. The efficacy of
antimigraine medications including amitriptyline,
cyproheptadine, propranolol and sumatriptan, as pro-
phylactic medications or to attenuate the severity and
T. L. Abell et al. Neurogastroenterology and Motility
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duration of cyclic vomiting episodes supports a com-
mon pathogenic link with migraines.2,25
Despite the common association of CVS with
migraine, CVS in children and adults is more than a
migraine variant as migraine headaches are not present
in all patients. Eighteen per cent of the paediatric series
reported by Li et al.2 had no evidence of a migraine
diathesis. These individuals tended to have longer
vomiting episodes and responded less well to antimi-
graine medications, suggesting different underlying
mechanisms of disease in those with and without
associated migraine.
Psychiatric disease Psychiatric disorders, including
anxiety and depression, are frequent comorbid findings
in patients with CVS.26 In individual cases, it is diffi-
cult to distinguish whether these conditions are con-
tributing factors towards the development of vomiting
episodes, the result of coping with an unexplained and
distressing illness, or whether common underlying
pathogenic factors predispose patients to both vomit-
ing episodes and psychiatric conditions. Findings sup-
port the perception that CVS is not psychologically
driven (psychogenic), but rather is a primary disorder,
associated with psychological comorbidity.27
There may be a subset of patients where CVS is a
manifestation of extreme anxiety, panic or unstable
mood. Panic disorder may be present in CVS and panic
attacks are anecdotally reported to trigger attacks in
two-thirds of adults.10 Identification and treatment of
panic disorder in patients with CVS can lead to a
reduction in CVS attacks.28 Therefore, it seems appro-
priate that clinicians consider panic disorder when
evaluating patients with CVS-like symptoms.
Marijuana use Marijuana use has been proposed as a
contributing factor in some patients with CVS.29,30 On
the other hand, marijuana is also used by patients to
reduce the nausea and vomiting. Allen et al.29 initially
described nine patients with a history of prolonged
cannabis abuse, predating the onset of the vomiting
illness. Hyperemesis followed a cyclical pattern every
few weeks or months, against a background of habitual
cannabis abuse and the taking of frequent warm
showers. Cessation of cannabis led to termination of
the cyclic emesis. In another series of adult patients
with CVS,14 a large number (13 of 31) of patients
reported daily marijuana use, but during follow-up,
only two patients that ceased marijuana use had reso-
lution of their vomiting cycles, whereas seven claimed
that marijuana improved their nausea, lessened anxi-
ety and hastened the return of normal appetite during
the recovery period. The role of marijuana as a causa-
tive or treatment agent in CVS remains unclear. It is
unknown if chronic marijuana use has deleterious
effects on the endogenous cannabinoid system or if
other constituents of the inhaled smoke from mari-
juana cigarettes accumulate in toxic quantities.
PATHOGENESIS AND
PATHOPHYSIOLOGY OF CVS
Scientific and therapeutic investigations have yet to
clarify the aetiopathogenesis of CVS. The recent rec-
ognition of the disease as an entity has led to increasing
interest in the cause of this disorder. Cyclic vomiting
syndrome has only recently been recognized to occur
in adults. Rigorous scientific and therapeutic investi-
gations have been difficult to perform as most centres
may only have identified a few cases. Multicentre
studies are difficult due to the acuity of the disease.
There is an emerging consensus that CVS appears to
involve dysregulated central neural pathways and
neuro-endocrine mediators involved in the afferent
and efferent brain–gut pathways of nausea and vomit-
ing.31 Despite an incomplete understanding of the
mechanisms underlying this dysregulation, important
advances are being made in the clinical understanding
of this disorder which may open the way for new
treatments. Several pieces of evidence from different
lines of investigation point towards an important role
of altered brain responses to visceral and to emotional
stimuli. Evidence has accumulated which suggest
additional pathogenic roles for autonomic, GI, central
neuroendocrine and mitochondrial metabolic factors.
One proposed model attempts to integrate the
various systems and pathways suggested to be involved
in CVS. This model suggests that common triggering
stressors (e.g. psychological, infectious) initiate the
vomiting cascade in subjects with specific susceptibil-
ity factors (e.g. family history of migraines, autonomic
and GI dysfunction, energy deficits due to mitochon-
drial dysfunction) that render affected individuals to
respond with repeated episodes of emesis. The defect
that enables this cascade to feed forward for hours to
days is unknown.
Possible pathophysiology of CVS
Triggering events Psychological or infectious stressors
are well known to initiate central arousal and the
cascade of hypothalamic-pituitary-adrenal (HPA) axis
activation. Specifically, the corticotropin-releasing
factor (CRF) signalling system is activated by stressors
(e.g. infections, psychological, energy depletion) and
plays an important role in mediating autonomic
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(sympathetic activation and vagal inhibition) altera-
tions that impact on gut motility.32–34 It is well rec-
ognized that various immunological, psychological or
physical stress can precipitate the episodic occurrence
of emesis in 70% of children with CVS.8 During the
past decade, functional magnetic resonance imaging
(fMRI) and positron emission tomography (PET) stud-
ies have helped identify and define central nervous
system abnormalities in patients with functional GI
disorders35 including CVS.36 Although inconsistencies
have been observed across different studies, there is
converging evidence of altered responsiveness of cen-
tral arousal circuits involving the amygdala, cingulate
cortical subregions and pontine regions, including the
peri-aqueductal grey region and the locus ceruleus
complex.37 It appears that several functional GI dis-
orders and other stress-sensitive disorders, such as
migraine headaches, share altered responsiveness and
modulation of central arousal circuits, including dys-
regulation of the periaqueductal grey (PAG) area. Pre-
liminary results from functional15 O-PET brain
imaging in adult patients with CVS suggest alterations
in brain areas that deal with heightened awareness and
anxiety (the cingulated cortices) as well as those
that deal with pain and pleasure (the inferior frontal
cortex).36
Susceptibility factors The linkage between CVS and
migraine headaches may indicate that migraines are
either an important factor in CVS pathogenesis or
merely a marker for a more generalized underlying
central nervous system disorder. Migraine headaches
involve both an electrophysiological event (spreading
depression) that corresponds to the clinical visual aura
and a cerebrovascular event with vascular dilation that
causes pain and further neural activation.38 In some
patients with a haemiplegic form of migraine, an ion
channelopathy, neuronal P/Q type calcium channel
associated with a CACNA1A gene mutation, increases
neuronal sensitivity to depolarization.39 Recent neuro-
imaging studies have identified the locus of migraine
activation in the brainstem. In one study, increased
blood flow in the cingulate, auditory and visual cor-
tices observed on PET scanning were reversed by the
antimigraine drug sumatriptan (5HT1B/1D agonist),
whereas brainstem activation patterns were not af-
fected.40 Similarly, in a second study on migraine and
cluster headaches, initial rostral brainstem activation
was unaffected by sumatriptan.41 The importance of
altered brainstem activation in patients with CVS is
unexplored.
The autonomic nervous system plays a prominent
role in the responses to a range of emetic activators. An
integrated series of brainstem nuclei receives input
from vagal and sympathetic afferent nerves during
emetic stimulation. Efferent signals are then generated
in the brainstem nuclei which initiate the stereotypic
and coordinated muscular actions involved in vomit-
ing. Using several tests of autonomic function includ-
ing postural adjustment ratio, heart rate variability, tilt
table and sudomotor testing, three groups of investiga-
tors have observed increases in sympathetic tone in
children with CVS.42–44 The most common shared
finding in these reports was an adrenergic abnormality,
but co-existent vagal cholinergic function abnormali-
ties was reported. Comorbid dysautonomic symptoms
commonly experienced by patients with CVS include
migraine headaches, gut dysmotility, complex regional
pain syndrome and postural orthostatic tachycardia
syndrome (POTS).45 Based on these studies describing
dysautonomic features in patients with CVS, investi-
gators have hypothesized that sympathetic autonomic
imbalance may render patients more susceptible to
over-respond to central emetic signals.
Gastric emptying and myoelectric activity have
been investigated in adult patients with CVS, primarily
during asymptomatic periods between emetic episodes.
Two groups have documented the presence of rapid
gastric emptying between attacks in adults with
CVS.14,16 In contrast, delayed gastric emptying during
the vomiting phase was observed in some patients
when this test was able to be performed.14 The delay in
gastric emptying during the symptomatic phase may
represent a generalized response to central nausea,
whereas rapid gastric emptying in the vomiting-free
period may indicate that there is an underlying auto-
nomic dysfunction as described above. Electrogastrog-
raphy (EGG) of patients with CVS demonstrates
prominent tachygastria and blunting of the amplitude
of waves in response to meal ingestion14,17,46 similar to
findings in individuals with idiopathic nausea and
vomiting syndromes. This may relate to the occur-
rence of coalescent nausea between vomiting episodes.
Small bowel dysmotility has also been reported in
patients with CVS.17
Cellular energy deficits resulting from mitochon-
drial dysfunction may contribute to the autonomic
dysfunction of CVS that could be present in patients
with CVS. As mitochondrial energy production is a
ubiquitous cellular function, mitochondriopathies
have a range of clinical presentations. Because of high
cellular energy demands, disorders of nerve and muscle
function are especially common.47 Defects in mito-
chondrial energy production due to mutations may
predispose individuals to the onset of vomiting during
periods of heightened demands for energy (e.g. stress,
T. L. Abell et al. Neurogastroenterology and Motility
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infections). The strong maternal bias of migraine and
other functional or dysautonomic conditions in CVS
kindreds suggests that mtDNA alterations (sequence
variations) could be contributing factors in the
pathogenesis of CVS (and migraine) in some
patients.2,24,48–50 Mitochondrial DNA is comprised 37
genes which are involved in energy metabolism and,
unlike nuclear DNA, is only maternally inherited
without recombination, and therefore affecting the
entire matrilineage (individuals related entirely
through women).47 Disordered mitochondrial metabo-
lism during emetic episodes is evidenced by elevated
urinary organic acids (e.g. Krebs cycle intermediates,
dicarboxylic acids) in patients with CVS similar to that
seen in patients with known mitochondrial disor-
ders.24,49 As in mitochondrial disorders, treatment
with intravenous dextrose appears to help relieve
symptoms in up to half of patients with CVS during
an episode, suggesting that the dextrose helped to
alleviate the energy deficit due to the underlying
mitochondrial defect.6,50 Recent studies characterized
heteroplasmic mutations (i.e. two species of mtDNA
present in the sample) and CVS and migraine-associ-
ated homoplasmic polymorphisms in the small (1 kDa)
mtDNA control region of a subset of children with
CVS.51–53
Mediators and pathways Potential neuroendocrine
mediators such as CRF and related downstream effec-
tor pathways – cortisol production and prostaglandins
E2 – as well as autonomic alterations may participate in
initiating or sustaining vomiting in CVS.
The classic function of CRF is to stimulate adreno-
corticotropic hormone (ACTH) production by the
anterior pituitary, thereby activating the HPA axis
and the stress response. In addition, CRF appears to
mediate anxiogenic, autonomic (sympathetic activa-
tion, vagal inhibition and sacral parasympathetic acti-
vation), and visceral (inhibition of gastric transit and
stimulation of colonic secretory and motor function)
responses to stress. Experimental studies show that
CRF pathways are activated by psychological or
immune (elevated levels of cytokines) stressors that
induce catecholamine release and reduced vagal effer-
ent activity that lead to hypertension and gastric stasis;
these responses can be prevented by CRF receptor
antagonists.54 Taché34 has proposed that altered CRF
receptor-mediated signalling plays a key role in trig-
gering emesis in patients with CVS. This concept is
supported by the similarity between clinical, endo-
crine, autonomic features in patients with CVS
and those elicited by brain CRF hyperactivity.34 Inter-
estingly, tricyclic antidepressants (TCAs) reduce
frequency of vomiting episodes and inhibit the pro-
moter activity of the CRF gene.34,55,56 A preliminary
study reports elevated peripheral CRF levels in affected
children during active vomiting episodes.57 However,
definitive proof of concept will require therapeutic
benefits of, as of yet unavailable, CRF receptor antag-
onists in the treatment of CVS episodes.
Prostaglandin pathways are activated by CRF and
can exert a positive feedback to induce CRF
release.58,59 The recruitment of CRF pathways can be
inferred from Sato et al.s19 initial report describing
overactivation of the HPA axis with development of
transient hypertension in a subset of children with
CVS (Sato variant). They found a rise in peripheral
levels of ACTH, cortisol, catecholamines (noradrena-
line and adrenaline), antidiuretic hormone (ADH) and
prostaglandin E2 (PGE2) preceding and during the early
part of the vomiting episode. The importance of
catecholamine and prostaglandin pathways in the
genesis of this variant is evidenced by the reduction
in symptom produced by the a-adrenoceptor agonist
clonidine and the prevention of vomiting episodes by
indomethacin pretreatment.19–21 In 1964, Wolff et al.60
described a patient with cyclic nausea and vomiting
associated with hypertension, abnormal glucose toler-
ance, elevated plasma ACTH and cortisol that could be
attenuated by high doses of dexamethasone. Underly-
ing hypothalamic derangements have also been sug-
gested in other paediatric CVS cases.61 Similarly,
Pasricha et al. describe an adult with CVS with
elevations in ACTH and cortisol preceding the attacks
of vomiting. Emetic episodes in this patient were
reduced by the non-steriodal agent ketorolac, raising
the possibility that both HPA axis derangement as well
as endogenous prostaglandin release participate in
symptom generation.22
DIAGNOSTIC TESTING FOR ADULTS
WITH PRESUMED CVS
The differential diagnosis of clinical disorders that can
mimic CVS is extensive and includes GI infections and
inflammatory conditions, disorders of gut motor func-
tion, eosinophilic oesophagitis or gastroenteritis, he-
patopancreaticobiliary disorders, surgically remediable
intra-abdominal abnormalities including bowel
obstruction, as well as a range of extra-abdominal
disorders including ureteropelvic junction obstruc-
tion.62,63 The initial evaluation of the patient with
presumed CVS should exclude these conditions.64,65
Table 4 lists disorders to exclude when considering
CVS in adult patients and the appropriate test to
evaluate for the disorders. Once a positive diagnosis of
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CVS is made by the characterization of the typical
clinical presentation and by the exclusion of other
disorders, subsequent diagnostic investigations gener-
ally are restricted to those tests that facilitate detection
of the complications of CVS including electrolyte
abnormalities, dehydration and GI haemorrhage.
Typical initial screening testing includes laboratory
tests (complete blood count and differential, glucose,
electrolytes, liver chemistries, pancreatic enzymes
and pregnancy test), urinalysis, and plain flat and
upright radiographic series to exclude abdominal
obstruction. It must be recognized that CVS can
produce misleading laboratory findings in some cases.
For example, neutrophilia without band forms can be
caused by stress-induced leucocyte demargination.
Lactic acidosis and ketosis are sequelae of prolonged
vomiting and fasting. High urine specific gravity,
often found with profound dehydration, may be
elevated instead as a result of increased ADH produc-
tion resulting from the patients nausea. Hyponatra-
emia with fluid retention can occur in some patients
with the Sato variant of CVS.20
The decision to perform additional testing must be
tailored to the individual patient presentation – the
history and physical examination with particular
attention to alarm findings including haematemesis,
pronounced abdominal tenderness with guarding or
rebound and neurological abnormalities such as altered
consciousness and lateralizing neurological findings.64
In many instances, it may be appropriate to consider
other tests including upper GI contrast radiography,
upper endoscopy, abdominal CT scanning or ultraso-
nography, and brain imaging with MRI to exclude
structural lesions of the brain, especially in the
posterior fossa. Endoscopy is considered for haemate-
mesis, which can be a consequence of the vomiting
either from a Mallory–Weiss tear or from prolapse
gastropathy in which the gastric cardia is forced into
the distal oesophagus by violent retching. In paediatric
patients, a renal ultrasound is often performed to
evaluate for hydronephrosis from ureteropelvic junc-
tion obstruction (Table 4). In adults, consideration
often is given to gastroparesis as an alternate diagnosis.
Indeed, a subset of patients with diabetic gastroparesis
presents with cyclic emetic episodes similar to
CVS.18,66 These individuals exhibit more severe gastric
retention than those with chronic symptoms. How-
ever, as observed in recent studies, rates of gastric
emptying often are accelerated rather than delayed in
patients with CVS during the asymptomatic period
when vomiting is absent allowing the test to be
performed.14,16
Table 4 Disorders that mimic cyclic
vomiting syndrome in adults
Disorder




Peptic ulcer disease Upper endoscopy
Gastroparesis gastric Emptying test
Gallbladder disorders
Cholecystitis Abdominal ultrasound



















Ureteropelvic junction obstruction Renal ultrasound
Hormonal and metabolic disorders
Adrenocortocoid insufficiency Plasma cortisol
Acute intermittent porphyria Urinary porphyrins
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Although metabolic disorders are more commonly
detected in children, if episodes are precipitated by
high protein meals, or if the patient suffers from a
comorbid neuromuscular condition, then evaluation is
performed to exclude metabolic disorders including
disorders of fatty acid oxidation (e.g. medium chain
acyl CoA dehydrogenase deficiency), mitochondriopa-
thies, urea cycle defects (e.g. partial ornithine transcar-
bamylase deficiency), acute intermittent porphyria (in
adolescents and adults) and disorders of ketolysis.
Similarly, endocrine evaluation for Addison disease
by measurement of a morning cortisol might be
considered.62 Blood tests to be obtained in this patient
subset may include glucose (hypo-or hyperglycaemia),
electrolytes (especially for the anion gap), lactic acid
levels, ammonia (to detect partial urea cycle enzyme
deficiencies and other conditions), fasting morning
cortisol, quantitative amino acid levels, carnitine, an
acylcarnitine profile and mtDNA analysis (including
testing for 3243A fi G and large rearrangements). In
general, blood and urine samples (ketones, organic
acids, carnitines and a porphyria screen) are optimally
obtained before giving i.v. dextrose.67
In a study of 225 children with episodes of cyclic
vomiting, 49% had an identified disorder other than
CVS that either caused or contributed to the vomit-
ing.62 In 12%, a serious surgical disorder was found in
the GI tract (malrotation), kidney (acute hydroureter),
or central nervous system (neoplasm). In 2%, Addisons
disease and metabolic disorders (disorders of fatty acid
metabolism) were found. Although 41% of children
with CVS had associated disorders that could poten-
tially contribute to the vomiting (mild oesophagitis
and chronic sinusitis), these were generally not
thought to be the cause based upon lack of response
to treatment. In this series, the tests with the highest
yield were endoscopy, sinus films and small bowel
radiography. Laboratory studies to screen for metabolic
or endocrine abnormalities were best performed during
the episodes to maximize the chance of detection of
potentially aetiological disorders.
Even though a comprehensive diagnostic evalua-
tion may be indicated in selected patients, the
clinician should be aware that most testing in
patients with idiopathic CVS symptoms will be
negative.10 Recent cost-effectiveness modelling stud-
ies in children suggest that it is most cost-effective to
begin prophylactic treatment in otherwise typical
patients rather than perform an extensive battery of
tests.68 The most cost-effective management strategy
was to image the upper GI tract and small bowel
through a barium series to exclude malrotation
followed by empiric antimigraine therapy – this
approach reduced costs by nearly half to $1600 and
reduced the number of upper endoscopies performed
by nearly two-thirds.
TREATMENT
Treatment of CVS in adults remains largely empiric
because of its elusive pathogenesis and the paucity of
controlled therapeutic trials.69 The overall approach to
treating a patient with CVS should include the
consideration of lifestyle modifications such as avoid-
ance of triggering factors, prophylactic drug therapy to
prevent recurrent episodes, abortive treatment and/or
supportive care to ameliorate acute episodes, and
psychological support of the patients and family. These
recommendations are based on open label trials
reported in case series and not generally on more
rigorous prospective clinical trials.
A placebo response rate of up to 70% in patients
with CVS has been reported following detailed consul-
tation and diagnosis alone without initiation of phar-
macotherapy.10 Another confounding variable in the
treatment is the heterogeneity of CVS that has been
observed in children, but likely also is present in
adults. Cyclic vomiting syndrome subgroups include:
(i) those with migraine; (ii) hypertension during epi-
sodes (Sato variant); (iii) catamenial CVS; (iv) diabetes
subgroup; (v) those with co-existing neuromuscular
disorders (CVS plus);45 (vi) association with extreme
anxiety; (vii) morning nausea and/or vomiting only;
and (viii) postinfectious subgroup. It is not known if
these different CVS subgroups exhibit different
responses to the varied treatments used for the
condition.
General approach
A multidisciplinary approach involving a supervising
gastroenterologist, the local primary care giver, as well
as nursing support and a psychologist, is useful for
management of CVS in children.70 Similar approaches
are likely to be beneficial in adults with CVS. An
important component to extend care of individuals
with CVS is to involve and educate the EDs as this is
where patients with CVS are usually managed during
the acute emetic phase. Providing the patient with a
letter from the supervising physician describing the
syndrome, the patients prior evaluation, and recom-
mending an appropriate individualized treatment plan
often helps facilitate timely, more effective treatment
and minimize unnecessary and repeated diagnostic
evaluations. Finally, the assurance of a prompt, pre-
dictable, effective treatment regimen can reduce the
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patient and family anxiety about the care of future
emetic episodes.
Frustrations resulting from a relapsing, disruptive
illness with frequent ED visits, common misdiagnosis,
extensive and redundant testing, mandate psychosocial
support for both patients and their families. The CVSA
is a non-profit organization that provides a support
network and education to patients and families,
distributes resources to professionals and supports
biomedical research. Cyclic Vomiting Syndrome Asso-
ciation has been helpful to paediatric and adult
patients, families and physicians. The CVSA patient
database now consists of more adult patients (some self
diagnosed) than children. The internet site for CVSA is
http://www.cvsaonline.org.
Lifestyle changes
Lifestyle changes may be instituted during the inte-
repisodic phase. Avoidance of excessive emotional
excitement, energy-depleted states (sleep deprivation,
fasting and illness), triggering foods (e.g. chocolate,
cheese, monosodium glutamate and red wine), motion
sickness and other identified triggers is helpful
(Table 5A). As with migraine headaches, eliminating
or stabilizing caffeine intake may be helpful. In some
women, episodes can be triggered by menses, so-called
catamenial CVS and pharmacological intervention to
cease menstruation can be considered. Diabetes needs
to be aggressively managed with the goal of glucose
control for blood glucose to remain <160 mg dL)1.
Episodes of hypoglycaemia must also be avoided as this
may also trigger episodes.
Prophylactic therapy
Recommendations for daily prophylactic pharmaco-
therapy to prevent future emetic episodes in the
patient with CVS are dependent on patient age, asso-
ciated medical and psychological comorbidities, the
dosage regimen and the side effect profiles of the
medications (Table 5A). Those patients with a higher
frequency (e.g. >one episode per month) and greater
severity of episodes (e.g. recurrent ER visits and/or
Table 5A Chronic prophylactic treatment
for cyclic vomiting syndromeLifestyle changes
Avoidance of potential triggers
Migraine headache
Excessive emotional excitement, anxiety, panic
Energy-depleted states (fasting, infections, illness)
Triggering foods (e.g. chocolate, cheese, MSG)
Motion sickness and other identified triggers
Menses: consider oral contraceptive agents
Relaxation routines
Controlling blood sugar in diabetic patients
Medications (prophylactic therapy to prevent subsequent episodes)
Tricyclic antidepressants
Amitriptyline, imipramine, or other tricyclic antidepressant; 10–100 mg day)1
Beta blockers




Cyproheptadine (Periactin) in children
Antianxiety medications
Lorazepam (Ativan) 1 mg dose up to 4 per day
Control comorbid symptoms, illnesses
For abdominal pain, address irritable bowel syndrome: use anticholinergic agents
or tramadol for pain
For breakthrough nausea, particularly in the amitriptyline, chlorazepam or sco-
polamine
patch
For gastro-oesophageal reflux symptoms, H2 blockers, proton pump inhibitors
For diabetic patients, maintain glucose at <160 mg dL)1 and prevent
hypoglycaemia
If menstrual cycles trigger an attack, consider Lupron injection or continuous birth
control to block menses
For morbid depression, psychiatry consultation
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hospitalizations, frequent absence from school or
work, failure to respond to abortive therapy) are most
likely to benefit from prophylactic treatment. Medica-
tions most often used for prophylaxis include TCA,
cyproheptadine and propranolol.
Tricyclic antidepressants are the most commonly
employed drug class for the prevention of CVS attacks
in adults.71,72 These agents also play a prophylactic role
in migraine, depression, anxiety and the abdominal
pain associated with irritable bowel syndrome and
presumably act centrally to modulate the vomiting
process.73 Low dose TCAs (25–50 mg day)1) induced
complete remission in nearly one of five patients and
partial response in over half of affected individuals in
one series.71 At higher TCA doses (e.g. amitriptyline at
1 mg kg)1 day)1), 93% of patients in a second series
experienced a decreased frequency and severity of
attacks while one-quarter achieved full remission.14
Treated patients reported improvement in anxiety and
mood symptoms, as well as prevention of migraine.
Based on these data and the personal experience of the
authors, amitriptyline is the preferred TCA to treat
adults with CVS. A step-up approach is typically
advocated for prescription of TCAs beginning with
low initial doses (e.g. 10 mg at night) with incremental
increases in dose (in some cases to 100 mg daily) to
titrate to the desired therapeutic effect. The rationale
for this approach is that lower doses may be therapeu-
tic in some cases and may limit side effects that can
occur with higher doses. Tricyclic antidepressants may
take up to a month to achieve full therapeutic effect
following initiation and each dose escalation. More
recently, the anticonvulsant agents zonisamide and
levetiracetam agents have demonstrated efficacy in
adult patients with CVS unresponsive or intolerant of
TCAs.74
For chronic prophylactic therapy, other consider-
ations may need to be addressed:
1 If amitriptyline dosing cannot be increased due to
side effects, TCAs with fewer side effects such as
nortriptyline, imipramine or desipramine can be
employed.
2 If there is a migraine component to the CVS attacks,
the b-adrenoceptor antagonist propranolol or in
children the histamine (H1)/serotonin receptor
antagonist cyproheptadine (periactin) can be used
or added to the TCA regimen providing bronchial
asthma has been excluded.
3 If anxiety is present during or between attacks,
benzodiazepines such as lorazepam (1 mg p.o. t.i.d.
initially) can be used.
4 Irritable bowel symptoms between acute attacks
attributed to the gastrocolonic reflex related to rapid
gastric emptying may respond to antispasmodic
agents such as dicyclomine.
5 If gastro-oesophageal reflux symptoms are present
after acute vomiting relapses, patients may need
1–2 months of a proton pump inhibitor which then
can be tapered.
6 Interepisodic nausea may necessitate the use of anti-
emetic agents such as ondansetron, promethazine, or
prochlorperazine.
7 Abdominal pain that does not fully subside between
attacks after may require tramadol and non-narcotic
analgesics. A very small subset unfortunately may
require narcotic use between episodes. Co-manage-
ment with a pain specialist is recommended for
these individuals.
8 For the subset of patients with significant depres-
sion, co-management with a psychiatrist may
be indicated to select antidepressant therapies with
the least likelihood of exacerbating the emetic
illness.
Acute abortive treatment during the prodromal
phase
A variety of therapies may be administered in some
cases during the prodromal phase to abort an oncoming
emetic episode (Table 5B). Supportive care is needed for
patients not responding to abortive treatment. The
treatment approach is largely adapted from clinical
experiences in treating CVS in children. There is a
paucity of data in both children and adults, and most
recommendations are based on medium-sized case
series and expert opinion.75,76
Table 5B Management during prodromal phase for cyclic
vomiting syndrome
Lifestyle changes/relaxation techniques
Decrease stress (lie down in dark, quiet room)
Consider hot bath or hot shower
Anti-emetics








5-HT1D agonist: sumatriptan, zolmitriptan, frovatriptan
Miscellaneous
High carbohydrate liquid ingestion
Consider ibuprofen
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Early pharmaceutical intervention during the pro-
dromal phase, similar to that employed for migraine,
may be effective in some cases. Administration of oral
non-steroidal anti-inflammatory drugs and ingestion of
caffeinated sweetened beverages are advocated by some
experts. Oral or intravenous dextrose also can truncate
episodes in some patients if given during the prodromal
phase or very early in the emetic episode. The most
useful pharmacological abortive approach endorsed by
the Pediatric Guidelines Committee of North Ameri-
can Society for Pediatric Gastroenterology, Hepatology
and Nutrition (NASPGHAN) is use of antimigraine
5HT1B/1D receptor agonists such as sumatriptan at the
earliest sign of an attack.75 These agents are more often
effective in children if there is a positive family history
of migraine, if administered early in the prodromal
phase or emetic phases, and if the episodes last <24 h.
Such drugs can be administered subcutaneously or
intranasally and can stop episodes within 30 min to
2 h in about half of the patients. The use of this class of
antimigraine drugs is less well studied in adult
patients.
Treatment during the vomiting phase
When the prodromal phase has progressed to relentless
emesis, evaluation and treatment in an ED or direct
admission to the hospital ward is often necessary to
relieve suffering and to prevent severe dehydration.
The goal during the vomiting phase is prompt treat-
ment to prevent dehydration and terminate the nausea
and vomiting. Treatments consist of hydration and
anti-emetic, antianxiety and/or analgesic medications
(Table 5C).
Intravenous fluid replacement is commonly required
to maintain hydration. Retrospective analyses have
suggested that 50% of CVS cases respond to intrave-
nous dextrose administration during the acute emetic
phase. The efficacy appears greater if higher concen-
trations of dextrose (e.g. 10% solutions) are adminis-
tered at 1.5 times the usual rate to reduce the ketosis in
the ED. As this treatment is benign, readily available,
inexpensive and often efficacious, it is recommended.
Anti-emetic agents can ameliorate the severity of
the vomiting episode, but usually do not abort the
attack. In children, the phenothiazine anti-emetics
(e.g. prochlorperazine) are generally not effective when
given alone. However, when given with an antihista-
mine such as diphenhydramine, symptom relief may
be observed in part due to the sedating effect of the
latter agent. 5-HT3 receptor antagonists such as ondan-
setron may be effective during the acute emetic phase
when administered in high doses.6 Ondansetron is
available in oral, sublingual and intravenous forms. All
anti-emetic therapies of CVS appear to be more effec-
tive when used in conjunction with sedatives.
The greatest relief is often achieved when a deep
sleep is induced which renders the patient insensible to
their intractable nausea and which also reduces antic-
ipatory anxiety related to the ongoing emetic episode.
In adults, sedation is most commonly provided by
intravenous administration of a benzodiazepine (e.g.
lorazepam). This should be given as quickly a possible
when a typical episode commences and the patient
presents to the ED setting (1–2 mg every 2 h). It should
be continued in the hospital if resolution cannot be
achieved in the ED. This approach also lessens the
need for narcotics and anti-emetics.
Abdominal pain may be a dominant symptom during
the acute emetic episode. In some cases, an intrave-
nous non-steroidal agent such as ketorolac may pro-
vide symptom relief. Other patients require narcotic
Table 5C Treatments during emetic phase for cyclic vomiting syndrome in adults
General Class Specific example
Supportive care Dark, quiet surroundings
Hydration Intravenous fluids D100.45 NS at 1.5 times maintenance
Anti-emetics 5-HT3 receptor antagonists Ondansetron
Phenothiazines with H1, D2, ACh blockade Promethazine, prochlorperazine
D2 receptor antagonists Metoclopramide, domperidone
Antihistamines Diphenhydramine
Anxiolytic Benzodiazepines Lorazepam
Analgesics NSAIDs Ketorolac i.v./i.m.
Opioids Hydromorphone (Dilaudid)
Fentanyl
Antimigraine 5-HT1B/1D agonist Sumatriptan
Gastric acid suppressants Proton pump inhibitors Omeprazole
H2 receptor antagonists Ranitidine
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analgesics for pain control. Opiates reduce CRF secre-
tion by the hypothalamus and have both analgesic and
anxiolytic effects. Some individuals will respond only
to very potent short acting agents such as hydromor-
phone.
Novel treatments
Pharmacological treatments for CVS are the focus of
ongoing research (Table 5D). Some patients with CVS
are already using agents purported to improve mito-
chondrial function. L-Carnitine is an amino acid-like
compound whose primary function is to transport long-
chain fatty acids into mitochondria for oxidation.77
Oral L-carnitine has been reported to reduce the
frequency of CVS attacks in some cases.78,79
Co-enzyme Q10, a hydrophobic substance, serves as
an electron carrier in the mitochondrial respiratory
chain and as an anti-oxidant. Although it has been
demonstrated efficacy in migraine headaches, the
utility of this agent in CVS has not been con-
firmed.80,81 Other pharmaceutical agents under con-
sideration for treatment of CVS include agents that
correct possible autonomic defects observed in CVS
(e.g. phentolamine82 as well as anti-emetic agents)
directed to novel receptors (e.g. the NK1 receptor
antagonist aprepitant).
Future directions
Cyclic vomiting syndrome has been best characterized
in children, but evidence has accumulated that a CVS-
like illness presents in adults which may be primary or
secondary to systemic disease or substance abuse. The
current understanding of the clinical spectrum of adult
CVS (including a broad agreement on the diagnostic
criteria for the disorder), factors involved in its path-
ogenesis, and therapies which prevent emetic episodes
or reduce symptoms once an episode is steadily
evolving. To date, information on the syndrome has
been provided by small to moderate sized single centre
case series amassed by a small number of experts in
CVS (Table 6). Further progress in understanding the
pathogenesis and improving diagnosis and treatment
approaches for CVS will be promoted by the following
strategies. Firstly, this consensus document prepared
by experts should be disseminated to gastroenterolo-
gists and other providers caring for adult patients to
enhance awareness and subsequently to more rapidly
diagnose the patient with CVS. Secondly, a registry of
adults who satisfy the diagnosis of CVS should be
established using non-restrictive inclusion criteria to
facilitate characterization of the spectrum of clinical
presentations. Such a registry could be accessible
online and could be maintained by a dedicated group
of expert investigators. Information provided by the
registry could help provide the basis for the develop-
ment of consensus diagnostic criteria for adults and the
construction of a diagnostic questionnaire. This regis-
try could help define relationships of adult CVS with
Table 6 Cyclic vomiting syndrome in adults: areas where re-
search is needed
Establish a consensus standardized questionnaire and
registry for adults with CVS
Validate diagnostic criteria in a well-defined clinical
population to further characterize the clinical phenotype
and prevalence of gastrointestinal and psychological
comorbid conditions
Establish the natural history in a prospective fashion
Increase awareness of CVS in adults
Gastroenterologists
Emergency room physicians




Autonomic nervous system dysfunction
Gastrointestinal motility relationships
Role of viral infections and other illnesses as triggers
Central nervous system imaging in patients with CVS
Before, during and after resolution of episode
Before and during treatment with resolution
Conduct multicentre trials on treatment of CVS in adults
Antimigraine therapies
Antidepressant therapies – amitriptyline
Anticonvulsant medications
Mitochondrial stabilizers – co-enzyme Q10, L-carnitine
Psycho-physiology and management of panic disorder in CVS
Management of CVS in pregnancy without the use of
potentially teratogenic agents
CVS, cyclic vomiting syndrome.
Table 5D Experimental therapy for cyclic vomiting syndrome
in adults
Mitochondrial stabilization
L-Carnitine 330 mg tablets: 2–3 tablets
two to three times daily,
up to 3 g day)1 > 8 weeks
Co-enzyme Q-10 up to 10 mg kg)1 day)1 >
8 weeks
Autonomic dysfunction




NK1 receptor antagonist Aprepitant (Emend)
Anti-epileptic agents Zonisamide, levetiracetam
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other systemic illnesses and quantify the prevalence of
comorbid GI disorders (e.g. irritable bowel syndrome,
gall bladder disease and sphincter of Oddi dysfunction)
and psychological conditions (e.g. anxiety and mood
disorders). The registry also could serve as a source of
potential subjects for future research into factors
underlying disease development and for placebo-con-
trolled, multicentre treatment trials. Such an approach
would confirm or refute the benefits of medication
classes such as antimigraine or anticonvulsant agents
in controlled trials, the uses of which currently are
supported only by anecdotal evidence. Examples of
ongoing research elucidating the underlying patho-
physiological mechanisms of CVS in adults specifically
include investigations of mtDNA mutations and mito-
chondrial dysfunction, and pilot studies on the role of
CRF in symptoms induced in the disorder. Establish-
ment of multicentre treatment trials will be challeng-
ing because of the need to generate a substantial
research infrastructure, initiate stable interinstitution-
al cooperative agreements and solicit government or
pharmaceutical funding.
SUMMARY
Cyclic vomiting syndrome is a debilitating functional
brain–gut disorder that was initially characterized in
children, but now is increasingly recognized to occur
also in adults. Although the prevalence is unknown,
the authors have observed a rapid rise in referrals for
adult patients with CVS over the last several years.
Although the pathogenesis remains unknown, several
promising avenues are being pursued including roles
for abnormal central nervous system processing,
aberrant CRF production, abnormal gastric emptying
suggesting dysautonomia and mitochondrial dysfunc-
tion. Based on small case series and expert opinions,
TCA appear useful as preventative agents and triptrans
are effective in some patients as an abortive agent.
Benzodiazepine sedatives can ameliorate symptoms
during acute emetic episodes with support from sero-
tonin 5-HT3 receptor antagonist anti-emetics and
NSAIDs or narcotic analgesics. This review might
serve as a catalyst to begin collaborative efforts to
enhance our understanding of the clinical features and
pathophysiology of the disease and to stimulate con-
trolled investigations into novel treatments for this
disabling condition.
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